Cambridge Healthtech Institute’s 6th Annual

Adoptive Cell Therapy – ACT 2

Engineering the Second Generation of CAR Ts, NKs, TCRs, and TILs

Part of The Immuno-Oncology Summit

August 5-6, 2019

Efforts to engineer CAR Ts, NKs, TCRs, and TILs with greater precision, safety profiles, and efficacy are leading to the second generation of improved adoptive cell therapies (ACT 2). With multiple engineered receptors already making preclinical impact, many biotech and pharma companies are preparing for the next wave of clinical trials. The end goal is still the same: improved patient outcomes. However, there remain technical considerations and translational challenges relating to cell therapy development, manufacturing practicability, clinical trial approaches, cell quality and persistence, and patient management. Cambridge Healthtech Institute’s Sixth Annual Adoptive Cell Therapy – ACT 2 conference focuses on the next steps needed for engineering CAR and delivering T Cells, NKs, TCR, and TIL therapies into the clinic.

CAR Ts

Keynote Presentation: Development of CAR T Cell Products: Lessons to Data and Implications to Next Generation Technologies
Adrian Bot, MD, PhD, Vice President, Translational Sciences, Kite, a Gilead Company

Advances in CAR-T Cell Therapy for Multiple Myeloma, Present and Future
Eric Smith, MD, PhD, Director, Translational Development - Cellular Therapeutics Center; Assistant Attending Physician - Myeloma Service, Memorial Sloan Kettering Cancer Center

Overcoming Resistance to CAR-T Therapy for Hematologic Malignancies
Marco Ruella, MD, Assistant Professor of Medicine and Scientific Director, Lymphoma Program, Division of Hematology and Oncology and Center for Cellular Immunotherapies, University of Pennsylvania

ACT

Altering T Cell Metabolism to Improve the Efficacy of Adoptive Cell Therapies
Sam Saibil, MD, PhD, Translational Research Fellow, Tumour Immunotherapy Program, Princess Margaret Cancer Centre

A Rare Population of Tumor Antigen-Specific CD4+CD8+ Double-Positive αβ T Lymphocytes Uniquely Provide CD8-Independent TCR Genes for Engineering Therapeutic T Cells
Junko Matsuzaki, PhD, Assistant Professor, Oncology; Director, Immune Analysis Shared Resource, Roswell Park Comprehensive Cancer Center

CAR CONSTRUCTS

Improving CAR T Cell Therapy through Reverse Engineering from Nature’s Designs
Michael C. Milone, MD, PhD, Associate Professor, Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania

Preclinical Evaluation of a CD19-Directed TAC T Cell Therapy Candidate for First-in-Human Clinical Trials
Christopher Helsen, PhD, Director, R&D, Triumvira

Modeling Anti-CD19 CAR T Cell Therapy in Humanized Mice
Yong-Guang Yang, MD, PhD, Professor, Columbia Center for Translational Immunology, Columbia University College of Physicians and Surgeons

For more details on the conference, please contact:
Mary Ann Brown
Executive Director, Conferences
Cambridge Healthtech Institute
Phone: (+1) 781-972-5497
Email: mabrown@cambridgeinnovationinstitute.com

For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com